WO1991009034A1 - Indolocarbazols provenant de saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951, atcc 53856 - Google Patents
Indolocarbazols provenant de saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951, atcc 53856 Download PDFInfo
- Publication number
- WO1991009034A1 WO1991009034A1 PCT/US1990/007174 US9007174W WO9109034A1 WO 1991009034 A1 WO1991009034 A1 WO 1991009034A1 US 9007174 W US9007174 W US 9007174W WO 9109034 A1 WO9109034 A1 WO 9109034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- subsp
- taken together
- och
- scc
- Prior art date
Links
- 229960005544 indolocarbazole Drugs 0.000 title claims abstract description 38
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 241000970318 Lechevalieria aerocolonigenes Species 0.000 title claims description 12
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 33
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 21
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 230000003276 anti-hypertensive effect Effects 0.000 claims abstract description 6
- 230000004663 cell proliferation Effects 0.000 claims abstract description 6
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 35
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 25
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 19
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 18
- 102000008089 Myosin-Light-Chain Kinase Human genes 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000204098 Saccharothrix Species 0.000 description 6
- 235000010633 broth Nutrition 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- -1 phosphatidylinositol mannosides Chemical class 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- KOZFSFOOLUUIGY-SOLYNIJKSA-N K-252a Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@](C(=O)OC)(O)[C@]4(C)O1 KOZFSFOOLUUIGY-SOLYNIJKSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000204094 Saccharothrix australiensis Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PWTCCMJTPHCGMS-KHPPLWFESA-N (2-acetyloxy-3-hydroxypropyl) (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CO)OC(C)=O PWTCCMJTPHCGMS-KHPPLWFESA-N 0.000 description 2
- XXCSQHMDTJAWNX-PVKGJVGDSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[(2s)-1-[[(2s)-4-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]- Chemical compound N([C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(N)=O)[C@@H](C)O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XXCSQHMDTJAWNX-PVKGJVGDSA-N 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 2
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 244000118681 Iresine herbstii Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001478477 Saccharothrix espanaensis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- XZPCNXORIOQSOG-UHFFFAOYSA-N TAN-1030A Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(=NO)C(OC)C4(C)O1 XZPCNXORIOQSOG-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- AMSOPBXQXSAAAC-UHFFFAOYSA-N ac1l1grw Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1C1(C)C(C(O)=O)(O)CC4O1 AMSOPBXQXSAAAC-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000035425 carbon utilization Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 108010046629 kemptamide Proteins 0.000 description 2
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- JYQQWQJCEUMXQZ-UHFFFAOYSA-N methyl cyanate Chemical compound COC#N JYQQWQJCEUMXQZ-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 1
- AMSOPBXQXSAAAC-PLZPTFKGSA-N 99570-78-2 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](C(O)=O)(O)C[C@H]4O1 AMSOPBXQXSAAAC-PLZPTFKGSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910004835 Na2B4O7 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000203619 Nocardiopsis dassonvillei Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- KDBQRAGSEVVHSN-UHFFFAOYSA-L copper(II) sulfate hexahydrate Chemical compound O.O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O KDBQRAGSEVVHSN-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002874 effect on oedema Effects 0.000 description 1
- 230000002857 effect on ulcer Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002811 myosin light chain kinase inhibitor Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZXQPCJUWQQAWKY-UHFFFAOYSA-N tan 999 Chemical compound C12=C3N4C5=CC(OC)=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(=NC)C(OC)C4(C)O1 ZXQPCJUWQQAWKY-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- This invention relates to indolocarbazotes, e xciuding the N-alkanoylstaurosporine derivatives, isolated from an antimicrobial, eg. antibacterial/ant ⁇ fungal indolocarbazole com plex produced by
- the indolocarbazoles of this invention exhibit selective pharmacological activities, for example in cardiovascular disorders; especially anti hypertensive activity, against proliferation of tumor cells, on inflammation as well as on microbial infections such as caused by bacteria or fungi.
- staurosporin derivative including N-acetyl staurosporine are disclosed in WIPO 89/07105 by Murakata et al. of KYOWA HAKKO KOGYO Co. Ltd. on August 1989 as protein Kinase C inhibitors and cell growth inhibitors.
- N-acetylstaurosporine is disclosed and in Australian Patent Application - 17571/88 by CIBA-Geigy on December 15, 1988 as a N-substituted derivative of staurosporine being capable of selective modification of the activity of protein kinase C and as such can be useful for the preventive or curative treatment of diseases in which the inhibition of protein kinase C is of importance in a warm blooded animal as well as can be employed as medicaments for tumor-inhibition, inflammation-inhibition, immunomodulation and also in preparations for combating bacterial infections, arteriosclerosis, as well as other diseases of the
- cardiovascular system cardiovascular system and of the central nervous system.
- novel indolocarbazoles of this invention have selective pharmacological properties which are distinguishable from those of the known indolocarbazoles.
- R a and R b are each H or R a and R b taken together are
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula I and a pharmaceutically acceptable carrier.
- the pharmaceutical composition of this invention may be administered to warm-blooded animals to inhibit myosin light chain kinase, protein kinase C or tumor cell proliferation or to produce an anti-hypertensive effect or an anti-inflammation effect.
- the present invention still further provides a method of treating a warm-blooded animal afflicted by hypertension, which comprises administering to said animal a therapeutically effective amount of a compound represented by formula I sufficient to treat hypertension or a pharmaceutical composition thereof.
- the present invention further provides a method of treating inflammation in a warm-blooded animal which comprising administering t ⁇ said animal an anti-inflammatory effective amount of a compound of formula I or a pharmaceutical composition thereof.
- the compounds of this invention are novel
- indolocarbazoles which are isolated. along with N-acetylstaurosporine and known indolocarbazoles such as staurosporine from an antibiotic complex produced by cultivating a strain of Saccharothrix
- aerocolonigenes subsp. copiosa subsp. nov, SCC 1951 having the identifying characteristics of ATCC 53856 in a pH and temperature controlled aqueous nutrient medium having assimilable sources of carbon and nitrogen under controlled submerged aerobic conditions until a composition of matter having substantial inhibition at myosin light chain kinase (“MLCK”) activity is produced.
- MLCK myosin light chain kinase
- This invention also provides a process for producing th e indolocarbazole complex of this invention which comprises cultivating an antibiotic complex producing strain of Saccharathrix
- indolocarbazoles of formula I is a biologically pure culture of the microorganisms Saccharothrix aerocolonigenes subsp. copiosa subsp. nov having the identifying characteristics of ATCC 53856, said culture being capable of producing an indolocarbazole complex in a
- the indolocarbazole compounds of this invention were isolated trom an imdolocabazole complex obtained from a culture broth produced by a fermentation under controlled conditions of a biologically pure culture of the microorganism, Saccharothrix aerocolonigenes suhsp-copiosa subsp nov. SCC 1951,.ATCC 53856.
- a viable culture of this microorganism has been deposited on January 17, 1989 in the collection of the American Type Culture Collection (ATCC) in Rockville, Md., where it has been assigned accession num ber ATCC 53856 and found viable on January 23, 1989.
- ATCC American Type Culture Collection
- Inoculum for the biochemical and physiological tests was prepared by adding 1.0 mL of thawed culture suspension to 10 mL of clear broth in a testrtube which was placed on a rotary shaker (300 rpm) at 28-30°C for 3 to 5 days. The culture was harvested by centrifugation and washed three times with distilled water. The final pellet was resuspended in distilled water to 4 times the packed cell volume.
- Incubation temperature for the biochemical and physiological tests was 28°C. Readings of the results were made at various times up to 21 days for the plate media. Most of the tubed media were read at weekly intervals for 4 to 6 weeks.
- Strain SCC 1951 was isolated from a soil collected in Spain and is a filamentous organism that forms a well developed, moderately branching substrate mycelium with hyphae approximately 0.4 ⁇ m to 0.6 ⁇ m in diameter. The vegetative mycelium fragments into coccoid to bacillary elements.
- Purified cell wall preparations of SCC 1951 analyzed by the method of Becker [Becker et al., Appl., Microbial.12, 421-423 (1964)] contain the meso-isomer of 2,-6-diaminopimelic acid, alanine, glutamic acid, glucosamine, muramic acid and galactose (Type III).
- Lechevalier, M.P., J. Lab. Clin. Med. 71 , 934-944 (1968)] contain gatactose, glucose, mannose, ribose, rhamnose and a trace of madurose.
- the method of Becker [Becker et al., Appl., Microbial.12, 421-423 (1964)] contain the meso-isomer of 2,-6-diaminopimelic acid, alanine, glutamic acid, glucosamine, muramic acid and galact
- phospholipids present are diphosphatidylglycerol, phosphatidylinositol, phosphatidylinositol mannosides, phosphatidylethanolamine acylated to both hydroxy and branched chain fatty acids and a minor unknown (Type PII).
- the substrate mycelium of SCC 1951 varies from cream to orange yellow to dark yellow brown to brownish black.
- the aeriat mycelium is usually white and tends to be thin.
- the white aerial mycelium turns yellow as it ages and:
- SCC 1951 was placed in the genus Saccharothrix.
- the description of SCC 1951 was compared with the descriptions of those Saccharothrix species listed on the Approved Lists of Bacterial Names or found in the patent literature: Saccharothrix australiensis. S. espanaensis., and S. aerocolonigenes.
- SCC 1951 is easily differentiated from S. australiensis and S. espanaensis.
- S. australiensis produces melanin, fails to grow on ISP 9 with any carbon source and does not hydrolyze starch or
- SCC 1951 The description of SCC 1951 , however, closely resembles that of S. aerocolonigenes and SCC 1951 was compared directly with S. aerocolonigenes ATCC 23870, the type strain. SCC 1951 differs from ATCC 23870 in producing acid from erythritol and destroying the cttror ⁇ ophore in phenol reef. SCC 1951 also produces a reddish orange to brownish orange soluble pigment on carbon utilization medium ISP 9 with trehalose, galactose or ribose as the carbon source. These pigments were never observed on the ATCC 23870 plates.
- Saccharothrix aerocolonigenes subsp. copiosa in reference to the large number of indolocarbazoles produced by this strain.
- PKC Protein kinase C
- Ca 2+ - and phospholipid-dependent protein kinase involved in mediating a wide variety of cellular responses to growth factors, hormones, oncogenes and other
- staurosporine and related indolocarbazoles, K252a, and K252b are inhibitory to PKC (from rats' brains) with good potency, in the nanomoiar range. Staurosporine has also been shown to inhibit the growth of cells at concentrations which correlate with in vitro PKC inhibition and to have antitumor activity in-vivo.
- staurosporine have high potency and thus are useful for biological studies but they have limited selectivity against protein kinases.
- H. Nako et al. J. Antibiot., (1987) Vol. 40. pp. 706-708] disclose that staurosporine, for example, will inhibit cyclic AMP-dependent protein kinase, myosin light chain kinase (MLCK) and p60v-src tyrosine kinase with similar potencies.
- MLCK myosin light chain kinase
- N-acetylstaurosporines is a potent inhibitor of PKC with increased selectivity compared to staurosporine as evidenced by comparison of inhibition of PKC to that of MLCK.
- Staurosporine and K- 252a have nanomolar potencies with MLCK to PKC ratios of 1.2 and 1.3 respectively.
- N-aoetytstaurasporine also ex hibits selective inhibition of MLCK and PKC with IC 50 's in the nanomolar range and has a MLCK to PKC ratio of 4.7.
- the PKC was partially purified fro m rat brain and assayed in the presence of its activators: Ca 2+ ; phosphatidyserine and 1-oleoyl-2-acetylglycerol. Histone lll-S was used as phosphate acceptor.
- the MLCK was native enzyme from chicken gizzard fully activated by calm ⁇ dulin. Kemptamide was usedas phosphate acceptor.
- the compounds with good potency for PKC inhibition as well as selectivity of PKC inhibition relative to other protein kinases indicate in vivo utility as potential antitumor agents.
- the compounds of this invention are potent inhibitors of PKC with increased selectivity compared to staurosporine as evidenced by comparison of inhibition of PKC to that of MLCK.
- Staurosporine and K-252a have nanomolar potencies with MLCK to PKC ratios of 1.2 and 1.3 respectively.
- the compounds of this invention exhibit selective inhibition of MLCK with IC 50 's in the range of 138 to > 1000 nM and PKC with IC 50 's in the range of 19 to 854 nM and MLCK to PKC ratios 1.2 to 18.8.
- the PKC was partially purified from rat brain and assayed in the presence of its activators: Ca 2+ , phosphatidylserine and 1-oleoyl-2- acetylglycerol.
- Histone lll-S was used as phosphate acceptor.
- the MLCK was native enzyme from chicken gizzard fully activated by calmodulin.
- Kemptamide was used as phosphate acceptor.
- the compounds with good potency for PKC inhibition as well as selectivity of PKC inhibition relative to other protein kinases indicate in vivo utility as potential antitumor agents.
- the compounds of this invention inhibited (a) serotonin release in human platelets which were prelabelled with [ 3 H] serotonin. Serotonin release from human platelets (IC 50 ranged from 0.95 to >50 ⁇ M) was measured following stimulation for one min with various doses of thrombin or at various times following addition of 1 unit/ml of thrombin. [T. Tohmatsu et al. Thrombosis Research, (1987), Vol. 47, pp. 25-35], (b) phorbot ester induced c-fos expression in cultured mouse BALB/C 3T3 cells which were exposed to the compounds of this invention for 20 hours prior to serum stimulation. The IC 50 's ranged from 0.6 ⁇ M to 5.4 ⁇ M. [T.
- the antibiotic complex of this invention as well as the individual indolocarbazoles of this invention isolated therefrom were shown to be myosin light chain kinase inhibitors and phosphodiesterase inhibitors and as such have utilation in treating cardiovascular disorders.
- the compounds of this invention exhibit antimicrobial properties and like K-252 indolocarbazoles exhibit diuretic properties.
- the compounds of this invention exhibit selective inhibition of MLCK and PKC and thus exhibit anti-proliferation activity against tumors cells.
- the present invention also provides a method of inhibiting tumor cell proliferation, which comprises contacting said tumor ceils with an anti-tumor cell proliferation effective amount of a compound of this invention represented by formula I or a pharmaceutical composition thereof.
- the present invention also provides a. method of treating a warm-blooded animal afflicted by hypertension which comprises administering to said animal a therapeutically effective amount of a compound represented by formula I sufficient to treat hypertension, or apharmaceutrcal com position of a com pound represented by formula I.
- the present invention provides a method of treating a warm-blooded animal afflicted with diseases wherein the inhibition of protein kinase C is of importance which comprises administering to said animal a therapeutically effective amount of a compound represented by formula I or a pharmaceutical composition thereof.
- the present invention provides a method of treating inflammation (arthritis, bursitis, tendonitis, gout as well as other inflammatory conditions) in a warm-blooded animal by administering to such an animal an anti-inflammatory effective amount of a compound of formula I or a pharmaceutical composition thereof.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of this invention represented by formula I or a pharmaceutically acceptable salt thereof, in racemic or optically active form and an inert pharmaceutically acceptable carrier or diluent.
- Typical suitable pharmaceutically acceptable salts are acid addition salts formed by adding to the compounds of this invention an equivalent of a mineral acid such as HCl, HF, HNO 3 , H 2 SO 4 or H 3 PO 4 or an organic acid, such as acetic, propionic, oxalic, valeric, oleic, palmitic, stearic, lauric, benzole, lactic, para-toluenesulfonic, methane sulfonic, citric, maleic, fumaric, succinic and the like.
- a mineral acid such as HCl, HF, HNO 3 , H 2 SO 4 or H 3 PO 4
- organic acid such as acetic, propionic, oxalic, valeric, oleic, palmitic, stearic, lauric, benzole, lactic, para-toluenesulfonic, methane sulfonic, citric, maleic, fumaric, succinic and the
- compositions may be made up by combining the compounds of this invention or a pharmaceutically acceptable salt thereof with any suitable, i.e., inert pharmaceutical carrier or diluent and administered orally, parentally or topically in a variety of formulations.
- suitable pharmaceutical co mpositions include solid compositions for oral administration such as tablets, capsules, pills, powders and granules, liquid compositions for oral administration such as solutions, suspensions or emulsions. They may also be
- the actual preferred dosages of the compounds of this invention or pharmaceutically acceptable salts thereof will vary according to the particular compound being used, the particular composition formulated, the mode of application and the particular situs, host and disease being treated. Many factors that modify the action of the drug will be taken into account by the attending clinician, e.g. age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease. Administration can be carried out
- Solvent used for column chromatography, and high pressure liquid chromatography (“HLPC”) were HPLC grade and not redistilled.
- Water refers to in-house deionized water passed through a Millipore Milli-Q purification system.
- the CHP-20P resin was purchased from Mitsubishi. Thin layer chromatography was carried out on
- anisaldehyde spray reagent High pressure liquid chromatography was carried out using Waters model 510 HPLC pumps controlled by a Waters automated gradient controller: Compounds were monitored at 300 nm using a Hewlett Packard 1040A photodiode array ultraviolet (UV) detector. Ultraviolet spectra were measured on the Hewlett Packard 1040A photodiode array detector or on a Hewlett Packard 8450A UV/Vis spectrophotometer; infrared spectra were measured on a Nicolet 10-MX instrument. 1 H and 13 C NMR spectra were measured on a Varian 400 instrument at 400 and 100 mHz, respectively.
- UV Hewlett Packard 1040A photodiode array ultraviolet
- the indolocarbazoles of this invention were isolated from an indolocarbazole complex which was produced by fermentation of a biologically pure culture of Saccharothrix aerocolonigenes subsp.
- the fermentation which produces the complex, was started using two or more inoculum stages.
- Medium for the inoculum stages are listed below.
- the inoculum and fermentation stages were conducted at a pH from about 6.4 to about 8.5, preferably about 7.0 for the inoculum stage and 7.5 for the fermentation stage.
- a temperature of about 27°C to 35°C was used to grow the inoculum stages, and to conduct the fermentation stage a temperature of about 27°C-35oC: was used
- Inoculum preparation was carried out in two stages for large scale fermentations (10L to 100L). Suitable nutrients for preparing the inocula are listed below:
- Five liters of the second stage inoculu m were used to inoculate 100L of the fermentation medium. The fermentation was conducted for 66 hours at 30°C in a 150L NBS Fermatron with agitation and aeration at 270 rpm and 1.8 cfm, respectively.
- the culture produced small quantities of a very complex mixture of indolocarbazoles.
- an analytical HPLC chromatogram of a partially purified sample of the complex mixture about 20
- indolocarbazole components including N-acetyl staurosporine were detected.
- the isolation of the indolocarbazole complex was accompllshed through a series of silica gel and reverse-phase chromatographies.
- the individual components were then obtained using size exclusion and reverse-phase semi-preparative HPLC. An exemplary procedure followed for various batch sizes is given hereinbelow.
- the oil was then subjected to a second silica gel column (6-7L) using 5% methanol in dichloromethane (v/v) as eluant; 1L cuts were taken and analyzed as above.
- the active fractions were then passed through a CHP-20P (IL) reverse-phase column and then eluted with 30, 50, 75 and 100% aq. ACN, the activity was found in the 50 and 75% fractions.
- the material in the active fractions were subjected to chromatography using a second CHP-20P column using a continuous gradient of 30 to 100% aqueous acetonitrile as solvent to produce partially purified material.
- the isolation of 2-3 component mixtures were achieved using LH-20 chromatography with 1 :1 dichloromethane/acetcnitrile as solvent.
- HPLC HPLC.
- the final step in purification was semi-preparative HPLC which was carried out on a YMC, C 18 reverse-phase column (15 ⁇ , 120 A, 30 x 500 mm) using a 30-40% aqueous acetonitrile gradient (UV at 375 nm, 35 mL/min flow rate). From 1000L batches, the indolocarbazole components (150 mg total) were isolated varying in weight from 1-30 mg including about 20 mg of N-acetyl-staurosporine.
- UV MEOH 207 (26,000), 239 (19,000), 292 (sh, 24,000 ⁇ , 301 (30,000), 330
- UV (MEOH); 206 (31,000), 238 (21,000), 293 (sh, 31,500), 300 (37,000), 340
- UV (MEOH) 208 (29,000) , 239 (25,000), 232 (sh, 26,000), 301 (49,000) , 340
- IR ( KBR) 3390, 1690, 1680, 1650, 1630, 1450, 1350, 1325, 1115, 1090, 1055
- N-acetylstaurosporine was prepared from staurosporine and a stoichiometric excess acetic anhydride in pyridine. The solution was stirred overnight at room temperature. The solvent was removed. The resulting solid was partitioned between ethyl acetate and water. The organic layer was washed with water then dried with anhydrous Na 2 SO 4 . Solvent was removed yielding N- acetylstaurosporine.
- N-substituted staurosporines may be prepared using the procedure of Example 2.
- N-propanoyl staurosporine N-propanoyl staurosporine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne les indolocarbozols représentés par la formule (I), dans laquelle Ra et Rb représente chacun H ou Ra et Rb pris ensemble représentent A ou B, dans lesquelles R1 et R2 représentent indépendemment H ou OH ou OCH3 et R3 représente OH, NHCH3, NCH3COCH3 ou NHCOCH3 et R4 représente OH ou H, et leurs isomères stéréochimiques ou leurs compositions pharmaceutiques utiles pour inhiber la kinase à chaînes légères de myosine, la kinase C protéique ou la prolifération de cellules tumorales, ainsi que pour produire un effet antihypertensif et un effet antiinflammatoire chez les animaux à sang chaud et chez l'homme, aux conditions que (1) lorsque Ra et Rb repreésentent ensemble A, et R1=H ou OH, R3 ne représente pas NHCH3; (2) lorsque Ra et Rb représentent ensemble B, alors R1=R4=H; (3) lorsque Ra=Rb=H R1=-OCH3, et (4) lorsque Ra et Rb représentent ensemble A, et R1=H, R3 ne représente pas (II).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45127189A | 1989-12-14 | 1989-12-14 | |
US45148789A | 1989-12-14 | 1989-12-14 | |
US451,271 | 1989-12-14 | ||
US451,487 | 1989-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991009034A1 true WO1991009034A1 (fr) | 1991-06-27 |
Family
ID=27036299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/007174 WO1991009034A1 (fr) | 1989-12-14 | 1990-12-12 | Indolocarbazols provenant de saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951, atcc 53856 |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7035991A (fr) |
IE (1) | IE904496A1 (fr) |
WO (1) | WO1991009034A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007153A1 (fr) * | 1991-10-10 | 1993-04-15 | Schering Corporation | Derives de staurosporine 4'-(n-substituee-n-oxydee) |
EP0541486A1 (fr) * | 1991-11-07 | 1993-05-12 | Ciba-Geigy Ag | Conjugates polycycliques |
EP0575955A1 (fr) * | 1992-06-22 | 1993-12-29 | Kyowa Hakko Kogyo Co., Ltd. | Procédé pour la préparation de dérivés de staurosporine |
WO1994016706A1 (fr) | 1993-01-28 | 1994-08-04 | Neorx Corporation | Inhibiteur therapeutique de cellules de muscles vasculaires lisses |
WO1995000520A1 (fr) * | 1993-06-17 | 1995-01-05 | Ciba-Geigy Ag | Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c |
US5382675A (en) * | 1993-05-07 | 1995-01-17 | Ciba-Geigy Corporation | Polycyclic compounds and processes for the preparation thereof |
WO1996013506A1 (fr) * | 1994-10-26 | 1996-05-09 | Cephalon, Inc. | Inhibiteurs de la proteine-kinase pour le traitement de troubles neurologiques |
US5547976A (en) * | 1992-03-20 | 1996-08-20 | Burroughs Wellcome Co. | Further indole derivatives with antiviral activity |
WO1999047522A1 (fr) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Derives de granulatimide utilises dans le traitement du cancer |
US6184217B1 (en) | 1996-06-25 | 2001-02-06 | Cephalon, Inc. | Use of K-252a derivative |
US6291447B1 (en) | 1998-03-13 | 2001-09-18 | The University Of British Columbia | Granulatimide compounds and uses thereof |
US6306849B1 (en) | 1996-06-03 | 2001-10-23 | Cephalon, Inc. | Selected derivatives of K-252a |
WO2003037347A1 (fr) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3 |
US6875865B1 (en) | 1996-06-03 | 2005-04-05 | Cephalon, Inc. | Selected derivatives of K-252a |
EP2098230A1 (fr) | 1997-03-31 | 2009-09-09 | Boston Scientific Scimed Limited | Utlisation des inhibiteurs cytosquelettiques en forme cristalline pour l'inhibition ou la prévention de la resténose |
ES2326459A1 (es) * | 2008-04-08 | 2009-10-09 | Universidad De Oviedo | Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos. |
EP2292225A1 (fr) | 1997-03-31 | 2011-03-09 | Boston Scientific Scimed Limited | Forme de dosage comprénant du taxol en forme cristalline |
CN106831898A (zh) * | 2016-12-27 | 2017-06-13 | 杭州科兴生物化工有限公司 | 具有蛋白激酶抑制活性的化合物及其制备方法和应用 |
CN107417751A (zh) * | 2017-06-15 | 2017-12-01 | 杭州科兴生物化工有限公司 | 吲哚咔唑类化合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303697A1 (fr) * | 1987-03-09 | 1989-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
WO1989007105A1 (fr) * | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
EP0328000A2 (fr) * | 1988-02-06 | 1989-08-16 | Gödecke Aktiengesellschaft | Dérivés d'indolocarbazole, procédé pour leur préparation et médicaments les contenant |
-
1990
- 1990-12-12 WO PCT/US1990/007174 patent/WO1991009034A1/fr unknown
- 1990-12-12 AU AU70359/91A patent/AU7035991A/en not_active Abandoned
- 1990-12-13 IE IE449690A patent/IE904496A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0303697A1 (fr) * | 1987-03-09 | 1989-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
WO1989007105A1 (fr) * | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
EP0328000A2 (fr) * | 1988-02-06 | 1989-08-16 | Gödecke Aktiengesellschaft | Dérivés d'indolocarbazole, procédé pour leur préparation et médicaments les contenant |
Non-Patent Citations (2)
Title |
---|
The Journal of Antibiotics, vol. 42, no. 2, November 1989, (Tokyo, JP), S. Tanida et al.: "Tan-999 and tan-1030A, new indolocarbazole alkaloids with macrophage-activating properties", pages 1619-1630 * |
The Journal of Antibiotics, vol. 43, no. 2, February 1990, (Tokyo, JP), H. Osada et al.: "A new inhibitor of protein kinase C, RK-286C (4'- demethlamino-4'-hydroxystaurosporine)", pages 163-167 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007153A1 (fr) * | 1991-10-10 | 1993-04-15 | Schering Corporation | Derives de staurosporine 4'-(n-substituee-n-oxydee) |
EP0540185A1 (fr) * | 1991-10-10 | 1993-05-05 | Schering Corporation | Dérivés de staurosporine-N-oxide N-substitués |
EP0541486A1 (fr) * | 1991-11-07 | 1993-05-12 | Ciba-Geigy Ag | Conjugates polycycliques |
US5264431A (en) * | 1991-11-07 | 1993-11-23 | Ciba-Geigy Corp. | Polycyclic conjugates |
US5547976A (en) * | 1992-03-20 | 1996-08-20 | Burroughs Wellcome Co. | Further indole derivatives with antiviral activity |
US5344926A (en) * | 1992-06-22 | 1994-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
EP0575955A1 (fr) * | 1992-06-22 | 1993-12-29 | Kyowa Hakko Kogyo Co., Ltd. | Procédé pour la préparation de dérivés de staurosporine |
US5741808A (en) * | 1992-07-24 | 1998-04-21 | Cephalon, Inc. | Protein kinase inhibitors for treatmen of neurological disorders |
US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
WO1994016706A1 (fr) | 1993-01-28 | 1994-08-04 | Neorx Corporation | Inhibiteur therapeutique de cellules de muscles vasculaires lisses |
EP2324829A1 (fr) | 1993-01-28 | 2011-05-25 | Boston Scientific Limited | Inhibiteur therapeutique de cellules de muscles |
EP2298310A2 (fr) | 1993-01-28 | 2011-03-23 | Boston Scientific Limited | Inhibiteur thérapeutique de cellules de muscles vasculaires lisses |
US5382675A (en) * | 1993-05-07 | 1995-01-17 | Ciba-Geigy Corporation | Polycyclic compounds and processes for the preparation thereof |
US5455241A (en) * | 1993-05-07 | 1995-10-03 | Ciba-Geigy Corporation | Polycyclic compounds and processes for the preparation thereof |
WO1995000520A1 (fr) * | 1993-06-17 | 1995-01-05 | Ciba-Geigy Ag | Compose d'indolocarbazole utilise comme inhibiteur de proteine-kinase c |
EP1125938A1 (fr) * | 1994-10-26 | 2001-08-22 | Cephalon, Inc. | Inhibiteurs de la proteine-kinase pour le traitement de troubles neurologiques |
WO1996013506A1 (fr) * | 1994-10-26 | 1996-05-09 | Cephalon, Inc. | Inhibiteurs de la proteine-kinase pour le traitement de troubles neurologiques |
US6875865B1 (en) | 1996-06-03 | 2005-04-05 | Cephalon, Inc. | Selected derivatives of K-252a |
US6306849B1 (en) | 1996-06-03 | 2001-10-23 | Cephalon, Inc. | Selected derivatives of K-252a |
US6184217B1 (en) | 1996-06-25 | 2001-02-06 | Cephalon, Inc. | Use of K-252a derivative |
EP2292225A1 (fr) | 1997-03-31 | 2011-03-09 | Boston Scientific Scimed Limited | Forme de dosage comprénant du taxol en forme cristalline |
EP2098230A1 (fr) | 1997-03-31 | 2009-09-09 | Boston Scientific Scimed Limited | Utlisation des inhibiteurs cytosquelettiques en forme cristalline pour l'inhibition ou la prévention de la resténose |
WO1999047522A1 (fr) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Derives de granulatimide utilises dans le traitement du cancer |
US6291447B1 (en) | 1998-03-13 | 2001-09-18 | The University Of British Columbia | Granulatimide compounds and uses thereof |
US7973031B2 (en) | 2001-10-30 | 2011-07-05 | Novartis Ag | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
WO2003037347A1 (fr) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3 |
US8222244B2 (en) | 2001-10-30 | 2012-07-17 | Novartis Ag | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
US8445479B2 (en) | 2001-10-30 | 2013-05-21 | Novartis Ag | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
WO2009125042A1 (fr) * | 2008-04-08 | 2009-10-15 | Universidad De Oviedo | Indolocarbazoles glycosylés, leur procédé d'obtention et leurs utilisations |
ES2326459A1 (es) * | 2008-04-08 | 2009-10-09 | Universidad De Oviedo | Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos. |
US8598132B2 (en) | 2008-04-08 | 2013-12-03 | Universidad De Oviedo | Glycosylated indolocarbazoles, method for obtaining same and uses thereof |
CN106831898A (zh) * | 2016-12-27 | 2017-06-13 | 杭州科兴生物化工有限公司 | 具有蛋白激酶抑制活性的化合物及其制备方法和应用 |
CN106831898B (zh) * | 2016-12-27 | 2019-06-18 | 杭州科兴生物化工有限公司 | 具有蛋白激酶抑制活性的化合物及其制备方法和应用 |
CN107417751A (zh) * | 2017-06-15 | 2017-12-01 | 杭州科兴生物化工有限公司 | 吲哚咔唑类化合物及其制备方法和应用 |
CN107417751B (zh) * | 2017-06-15 | 2019-11-22 | 杭州科兴生物化工有限公司 | 吲哚咔唑类化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
IE904496A1 (en) | 1991-06-19 |
AU7035991A (en) | 1991-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991009034A1 (fr) | Indolocarbazols provenant de saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951, atcc 53856 | |
EP0271581A1 (fr) | Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation | |
GB2147582A (en) | Bbm-2478 antibotic complex | |
US7199121B2 (en) | Protein tyrosine phosphatase inhibitor | |
EP0182152B1 (fr) | Antibiotiques antitumoraux (complexe LL-E33288) | |
US5618809A (en) | Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856 | |
KR100659680B1 (ko) | 항생 물질 카프라자마이신류 및 그 제조법 | |
EP1285928B1 (fr) | Antibiotiques tripropeptines et leur procede de production | |
US4551533A (en) | Antibiotic LL-D42067α | |
SU867318A3 (ru) | Способ получени баумицина а и в | |
EP1129208B1 (fr) | Vancoresmycine, son procede d'elaboration, et son utilisation comme produit pharmaceutique | |
EP0300294B1 (fr) | Composé DC-107 et son procédé d'obtention | |
EP0702691B1 (fr) | Nouveau thiodepsipeptide isole d'un actinomycete marin | |
US4743594A (en) | Antibiotic, antitumor compounds and their use | |
US4774184A (en) | Culture and process for producing antibiotic LL-D42067alpha | |
EP0721985B1 (fr) | Substance it-62-b et composition medicinale la contenant | |
EP1259523B1 (fr) | Pluraflavines et leurs derives, processus de preparation et utilisation correspondante | |
AU616946B2 (en) | Antibacterial and antitumor agents ll-e33288epsilon-i and ll-e33288-epsilonbr, with processes and intermediates for producing said agents | |
US5427941A (en) | Actinomadura brunnea var. antibiotica strains | |
US5171740A (en) | Coumamidine compounds | |
EP0423247B1 (fr) | Composes de coumamidine | |
EP0289354A2 (fr) | L'antibiotique TAN-950A, sa production et son utilisation | |
JP2000239292A (ja) | 抗mrsa抗生物質 | |
JPH04210676A (ja) | 抗腫瘍性物質be−18591 | |
JPH06279481A (ja) | Ws64826物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: CA |